

**Regulatory Procedures**

We follow Administrative Procedure Act (APA) rulemaking procedures specified in 5 U.S.C. 553 when we develop regulations. Section 702(a)(5) of the Social Security Act, 42 U.S.C. 902(a)(5). The APA provides exceptions to its notice and public comment procedures when an agency finds there is good cause for dispensing with such procedures because they are impracticable, unnecessary, or contrary to the public interest. 5 U.S.C. 553(b)(B). The change we are making in this rule only corrects an error in a cross-reference. Because the change we are making is only a minor technical correction to a rule to correct an outdated cross-reference, we have determined that the opportunity for prior comment is unnecessary. Therefore, we are issuing this rule as a final rule.

In addition, we find that there is good cause for dispensing with the 30-day delay in the effective date of a substantive rule provided by 5 U.S.C. 553(d)(3). For the reasons already discussed, because this change is a minor technical correction to a rule, a delay in the effective date is unnecessary.

*Executive Order 12866, as Supplemented by Executive Order 13563*

We consulted with the Office of Management and Budget (OMB) and determined that this final rule does not meet the requirements for a significant regulatory action under Executive Order 12866, as supplemented by Executive Order 13563. Therefore, it was not subject to OMB review.

*Regulatory Flexibility Act*

We certify that this final rule will not have a significant economic impact on a substantial number of small entities because it affects only individuals. Therefore, a regulatory flexibility analysis was not required under the Regulatory Flexibility Act, as amended.

*Paperwork Reduction Act*

This rule does not create any new or affect any existing collections, and therefore, does not require Office of Management and Budget approval under the Paperwork Reduction Act. (Catalog of Federal Domestic Assistance Program Nos. 96.001, Social Security—Disability Insurance; 96.002, Social Security—Retirement Insurance; 96.004, Social Security—Survivors Insurance; and 96.006, Supplemental Security Income)

**List of Subjects in 20 CFR Part 404**

Administrative practice and procedure, Blind, Disability benefits, Old-Age, Survivors, and Disability Insurance, Reporting and recordkeeping requirements, Social Security.

**Michael J. Astrue,**  
*Commissioner of Social Security.*

For the reasons set out in the preamble, we are amending subpart P of part 404 of chapter III of title 20 of the Code of Federal Regulations as set forth below:

**PART 404—FEDERAL OLD-AGE, SURVIVORS AND DISABILITY INSURANCE (1950– )**

■ 1. The authority citation for subpart P of part 404 continues to read as follows:

**Authority:** Secs. 202, 205(a)–(b), and (d)–(h), 216(i), 221(a), (i), and (j), 222(c), 223, 225, and 702(a)(5) of the Social Security Act (42 U.S.C. 402, 405(a)–(b), and (d)–(h), 416(i), 421(a), (i), and (j), 422(c), 423, 425, and 902(a)(5)); sec. 211(b), Pub. L. 104–193, 110 Stat. 2105, 2189; sec. 202, Pub. L. 108–203, 118 Stat. 509 (42 U.S.C. 902 note).

■ 2. Amend appendix 1 to subpart P of part 404 by revising section 111.09C of part B to read as follows:

**APPENDIX 1 TO SUBPART P OF PART 404—LISTING OF IMPAIRMENTS**

\* \* \* \* \*

*Part B*

\* \* \* \* \*

111.00 [*Neurological*]

\* \* \* \* \*

111.09 \* \* \*

C. Impairment of hearing as described under the criteria in 102.10 or 102.11.

\* \* \* \* \*

[FR Doc. 2011–6983 Filed 3–23–11; 8:45 am]

**BILLING CODE 4191–02–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Parts 510 and 529**

[Docket No. FDA–2010–N–0002]

**New Animal Drugs; Change of Sponsor’s Name and Address; Corrections**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Correcting amendments.

**SUMMARY:** The Food and Drug Administration (FDA) published a document in the **Federal Register** of

April 20, 2010 (75 FR 20522) amending the animal drug regulations to reflect changes to a sponsor’s name and address. That document contained errors in the regulatory text. FDA is correcting the tables listing sponsors of approved animal drug applications (NADAs) by adding a change to the sponsor’s drug labeler code (DLC). Cross-references to the sponsor’s DLC are amended in two sections of the Code of Federal Regulations (CFR) containing the conditions of use approved animal drug products. These corrections are being made to improve the accuracy of the animal drug regulations.

**DATES:** This rule is effective March 24, 2011.

**FOR FURTHER INFORMATION CONTACT:** George K. Haibel, Center for Veterinary Medicine (HFV–6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276–9019, e-mail: *george.haibel@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** The Food and Drug Administration (FDA) published a document in the **Federal Register** of April 20, 2010 (75 FR 20522) amending the animal drug regulations to reflect changes to a sponsor’s name and address. That document contained errors in the regulatory text. FDA is correcting the tables listing sponsors of approved animal drug applications (NADAs) by adding a change to the sponsor’s drug labeler code (DLC). Cross-references to the sponsor’s DLC are amended in two sections of the Code of Federal Regulations (CFR) containing the conditions of use approved animal drug products. These corrections are being made to improve the accuracy of the animal drug regulations.

**List of Subjects**

*21 CFR Part 510*

Administrative practice and procedure, Animal drugs, Labeling, Reporting and Recordkeeping requirements.

*21 CFR Part 529*

Animal drugs.

Accordingly, 21 CFR parts 510 and 529 are corrected by making the following correcting amendments:

**PART 510—NEW ANIMAL DRUGS**

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. In § 510.600, in the table in paragraph (c)(1), revise the entry for “Piramal Critical Care, Inc.”; and in the table in paragraph (c)(2), remove the

entry for "060307" and in numerical sequence, add an entry for "066794" to read as follows:

**§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.**

\* \* \* \* \*

(c) \* \* \*

(1) \* \* \*

Firm name and address	Drug labeler code
* * * * *	*
Piramal Critical Care, Inc., 3850 Schelden Circle, Bethlehem, PA 18017 .....	066794
* * * * *	*

(2) \* \* \*

Drug labeler code	Firm name and address
* * * * *	*
066794 ....	Piramal Critical Care, Inc., 3850 Schelden Circle, Bethlehem, PA 18017.
* * * * *	*

**PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS**

■ 3. The authority citation for 21 CFR part 529 continues to read as follows:

Authority: 21 U.S.C. 360b.

**§ 529.1186 [Corrected]**

■ 4. In paragraph (b) of § 529.1186, remove "060307, and 065085" and in its place add "065085, and 066794".

**§ 529.2150 [Corrected]**

■ 5. In paragraph (b) of § 529.2150, remove "060307" and in its place add "066794".

Dated: March 17, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2011-6795 Filed 3-23-11; 8:45 am]

BILLING CODE 4160-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 529**

[Docket No. FDA-2010-N-0002]

**Certain Other Dosage Form New Animal Drugs; Detomidine; Correction**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Correcting amendment.

**SUMMARY:** The Food and Drug Administration (FDA) published a document in the **Federal Register** of April 23, 2010 (75 FR 21162), that amended the animal drug regulations to reflect approval of an original new animal drug application (NADA). FDA is correcting a paragraph describing limitations to the approved conditions of use for detomidine hydrochloride oromucosal gel in horses. This correction is being made to improve the accuracy of the animal drug regulations.

**DATES:** This rule is effective March 24, 2011.

**FOR FURTHER INFORMATION CONTACT:** George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, e-mail: *George.Haibel@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** FDA published a document in the **Federal Register** of April 23, 2010 (75 FR 21162), that amended the animal drug regulations to reflect approval of an original NADA. FDA is correcting a paragraph describing limitations to the approved conditions of use for detomidine hydrochloride oromucosal gel in horses. This correction is being made to improve the accuracy of the animal drug regulations.

**List of Subjects in 21 CFR Part 529**

Animal drugs.

Accordingly, 21 CFR part 529 is corrected by making the following correcting amendment:

**PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS**

■ 1. The authority citation for part 529 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 2. In § 529.536, amend paragraph (c)(3) by adding a sentence after the first sentence to read as follows:

**§ 529.536 Detomidine.**

\* \* \* \* \*

(c) \* \* \*

(3) \* \* \* Do not use in horses intended for human consumption.

Dated: March 17, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2011-6791 Filed 3-23-11; 8:45 am]

BILLING CODE 4160-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 558**

[Docket No. FDA-2010-N-0002]

**Animal Drugs, Feeds, and Related Products; Withdrawal of Approval of New Animal Drug Applications; Aklomide; Levamisole Hydrochloride; Nitromide and Sulfantran; Roxarsone; Correction**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Correcting amendment.

**SUMMARY:** The Food and Drug Administration (FDA) published a document in the **Federal Register** of October 26, 2010 (75 FR 65565) amending the animal drug regulations. The October 26, 2010, final rule amended the regulations by removing those portions that reflect approval of eight new animal drug applications. The final rule inadvertently failed to add conforming amendments in § 558.530. FDA is correcting the animal drug regulations by removing cross references for use of the withdrawn drugs in combination drug medicated feed. This correction is being made to improve the accuracy of the animal drug regulations.

**DATES:** This rule is effective March 24, 2011.

**FOR FURTHER INFORMATION CONTACT:** George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, e-mail: *george.haibel@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** The Food and Drug Administration (FDA) published a document in the **Federal Register** of October 26, 2010 (75 FR 65565) amending the animal drug regulations. The October 26, 2010, final rule amended the regulations by removing those portions that reflect approval of eight new animal drug applications. The final rule inadvertently failed to add conforming amendments in § 558.530. FDA is correcting the animal drug regulations by removing cross references for use of the withdrawn drugs in combination